Human HCAR2/Apoaequorin Stable Cell Line-CHO

Nicotinic acid (niacin), a vitamin of the B complex, is used clinically in high doses to decrease total plasma levels of cholesterol. Interestingly, the total cholesterol levels and low-density lipoprotein (LDL) concentrations decrease, while the high-density lipoprotein (HDL) concentrations increase with nicotinic acid treatment. The cholesterol-lowering effects of nicotinic acid result from inhibition of lipolysis in adipose tissue, which decreases plasma levels of free fatty acid (FFA). In a study of nicotinic acid and myocardial infarction in the Coronary Drug Project (1966-1975), patients receiving 3 g/day nicotinic acid exhibited reduced rates of myocardial infarction. However, an unwanted effect of high doses of nicotinic acid is vasodilatation, occurring mainly in the upper body and face, known as flushing. Recently two receptors for nicotinic acid have been identified as class A G protein-coupled receptors that couple to Gi to inhibit accumulation of cAMP. GPR109A (also known as HM74A in humans and PUMA-G in mice) is a high affinity receptor for nicotinic acid, whereas GPR109B (also known as HM74) is a low affinity receptor for nicotinic acid that is found in humans but not rodents. GPCR109A is found primarily in adipose tissue and immune cells.

Product Information
Catalog #:	ACC-RG1315
Gene Name	HCAR2
Abbr	CHO-HuHCAR2/Apoaequorin
Alias	HCAR2,GPR109A,HCA2,HM74A,NIACR1,PUMAG,HM74a,HM74b,Puma-g,GPR109A
Growth Properties	Adherent
Host Cell	CHO-K1
Morphology	Epithelial-like
Shipping	Dry ice
Product Type	GPCR Expressing Cell
Species	Human
Product Format	frozen
searchKeyword	HCAR2,GPR109A,HCA2,HM74A,NIACR1,PUMAG,HM74a,HM74b,Puma-g,GPR109A